Monoclonal antibodies for asthma and chronic obstructive pulmonary disease
SA Antoniu - Expert Opinion on Biological Therapy, 2013 - Taylor & Francis
Expert Opinion on Biological Therapy, 2013•Taylor & Francis
Introduction: In asthma and chronic obstructive pulmonary disease (COPD), the
inflammation in the airways cannot always be controlled with conventional therapies, such
as inhaled corticosteroids. Addition of more specific anti-inflammatory therapies, such as
monoclonal antibodies, against inflammation pathways might improve the disease outcome.
Areas covered: This review individually discusses the major inflammation pathways and
their potential blocking monoclonal antibodies in asthma and COPD. Expert opinion: The …
inflammation in the airways cannot always be controlled with conventional therapies, such
as inhaled corticosteroids. Addition of more specific anti-inflammatory therapies, such as
monoclonal antibodies, against inflammation pathways might improve the disease outcome.
Areas covered: This review individually discusses the major inflammation pathways and
their potential blocking monoclonal antibodies in asthma and COPD. Expert opinion: The …
Introduction: In asthma and chronic obstructive pulmonary disease (COPD), the inflammation in the airways cannot always be controlled with conventional therapies, such as inhaled corticosteroids. Addition of more specific anti-inflammatory therapies, such as monoclonal antibodies, against inflammation pathways might improve the disease outcome.
Areas covered: This review individually discusses the major inflammation pathways and their potential blocking monoclonal antibodies in asthma and COPD.
Expert opinion: The current use of omalizumab in asthma provides a good example on the potential therapeutic role of monoclonal antibodies in both asthma and COPD. There are many other monoclonal antibodies which are currently investigated as possible therapies in these diseases. The identification of the disease subsets in which such antibodies might exert the maximum benefit opens the door for personalized medicine and for targeted biological therapy in asthma and COPD.
Taylor & Francis Online